Core Viewpoint - Medtronic plc will announce its financial results for the third quarter of fiscal year 2026 on February 17, 2026, following the end of the quarter on January 23, 2026 [1] Group 1: Financial Reporting - A video webcast discussing the financial results will begin at 7:00 a.m. CST on the announcement day [1] - A news release containing summary financial information will be issued at approximately 5:45 a.m. CST [1] - A replay and transcript of the prepared remarks will be available within 24 hours of the webcast [1] Group 2: Company Overview - Medtronic is headquartered in Galway, Ireland, and is a leading global healthcare technology company [1] - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions with its technologies and therapies [1] - Medtronic's mission is to alleviate pain, restore health, and extend life, focusing on innovative solutions in various medical fields [1]

Core Insights - Medtronic (MDT) is expected to report quarterly earnings of $1.33 per share, a decline of 4.3% year-over-year, with revenues projected at $8.9 billion, reflecting a 7.3% increase compared to the previous year [1] Revenue Estimates - Analysts estimate 'Net Sales- World Wide Revenue- Cardiovascular' to be $3.37 billion, indicating a year-over-year increase of 10.8% [4] - 'Net Sales- World Wide Revenue- Neuroscience' is projected to reach $2.59 billion, reflecting a 5.3% increase year-over-year [4] - 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' is expected to be $1.32 billion, a 6% increase from the prior year [5] - 'Net Sales- World Wide Revenue- Neuroscience- Neuromodulation' is forecasted at $505.68 million, indicating a 6.2% year-over-year change [5] U.S. Revenue Estimates - 'Net Sales- U.S. Revenue' is anticipated to be $4.53 billion, suggesting a 6.9% increase year-over-year [6] - 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' is projected at $342.56 million, reflecting a 4.8% increase [6] International Revenue Estimates - 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' is expected to reach $338.62 million, indicating a 10.3% year-over-year change [6] - 'Net Sales- ROW- Neuroscience- Specialty Therapies' is projected at $335.35 million, reflecting a 7.1% increase [7] - 'Net Sales- ROW- Cardiovascular- Cardiac Rhythm & Heart Failure' is expected to be $826.64 million, indicating a 7.4% increase [8] - 'Net Sales- ROW- Diabetes' is projected at $522.47 million, reflecting a significant 14.3% increase from the previous year [8] - The consensus estimate for 'Net Sales- ROW- Cardiovascular' stands at $1.77 billion, indicating an 8.5% year-over-year change [8] Stock Performance - Medtronic shares have shown a return of +5.2% over the past month, outperforming the Zacks S&P 500 composite, which has seen a -0.3% change [9]

医疗器械公司正把AI快速嵌入手术与诊断设备，把"智能化"作为增长卖点的同时，也把新的故障模式与 责任风险带进医院，监管机构收到的疑似伤害与故障申报正在上升。 据路透对安全与法律记录的梳理，以及对医生，护士，科学家和监管人士的采访，美国食品药品监督管 理局（FDA）近年收到的报告中，已出现手术导航误导、心律异常漏报，以及产前超声"错认身体部 位"等问题。 在具体案例上，医疗保健巨头强生旗下医疗器械公司Acclarent于2021年宣布为鼻窦手术导航系统TruDi 引入机器学习算法。 路透称，该设备上市约三年后才加入AI功能。加入AI之前，FDA收到关于设备故障的未证实报告为7 起，另有1起患者受伤报告；加入AI之后，FDA收到的未证实故障与不良事件报告至少达到100起。 路透援引相关报告称，至少10人在2021年末至2025年11月间受伤，多数事件据称与TruDi向术者错误提 示器械在颅内的位置有关。报告描述的后果包括脑脊液从鼻腔渗漏、误穿颅底，以及因大动脉意外受损 而导致的卒中等。 两名卒中患者在得州提起诉讼，指称TruDi系统的AI促成了伤害。其中一份诉状称，该产品在集成AI之 前"可能更安全"。Integ ...

Tuesday features AstraZeneca PLC and Coca-Cola Company (The) pre-market, with numerous healthcare and financials reports. Wednesday highlights McDonald's Corporation, T-Mobile US Inc., and Cisco Systems Inc. for technology earnings. Thursday brings Applied Materials Inc. after market. Energy majors lead a lighter Friday, while Next Tuesday concludes with Medtronic plc. and Palo Alto Networks Inc.. Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are no ...

Core Viewpoint - Medtronic (MDT) is expected to report its third-quarter fiscal 2026 results on February 17, with earnings per share (EPS) anticipated at $1.33, reflecting a 4.3% decrease year-over-year, while revenues are projected to reach $8.90 billion, indicating a 7.3% growth from the previous year [1][2]. Group 1: Q3 Estimates and Performance - The Zacks Consensus Estimate for Medtronic's third-quarter revenues is $8.90 billion, suggesting a 7.3% increase from the same quarter last year [2]. - The earnings estimate for the third quarter has been revised down by 1 cent to $1.33 per share over the past 60 days [3]. - Medtronic has consistently beaten earnings estimates in the last four quarters, with an average beat of 2.75% [1]. Group 2: Segment Performance Expectations - The Cardiovascular segment is projected to grow by 10.8% year-over-year, driven by the Cardiac Ablation Solutions business and strong performance from the Affera mapping system and Sphere-9 catheter [6][4]. - The Neuroscience segment is expected to see a revenue increase of 5.2% year-over-year, supported by the spine AiBLE ecosystem and growth in Core Spine and Neurosurgery [9][7]. - The Diabetes unit is anticipated to deliver an 11.5% revenue growth, bolstered by new product launches and pent-up demand [15][12]. Group 3: Challenges and Innovations - The Medical Surgical segment has faced challenges due to market pressures from bariatric surgery and a shift towards robotic surgery, but the FDA clearance for the Hugo robotic-assisted surgery system is a positive development [10]. - The Endoscopy business is expected to perform well, driven by growth in esophageal products and the AI-powered GI Genius solution [11]. - Medtronic's Diabetes business is in a strong innovation cycle, with the MiniMed 780G system receiving multiple approvals and a broad U.S. commercial launch [13]. Group 4: Strategic Developments - Medtronic has filed a registration statement for a proposed initial public offering (IPO) as part of a planned separation, allowing the company to focus on high-margin growth markets [14].

Core Viewpoint - A California court has ordered Medtronic to pay Applied Medical nearly $382 million in damages for monopolistic practices in the bipolar electrosurgical devices market [1] Group 1: Lawsuit Details - Applied Medical filed a lawsuit in February 2023, alleging that Medtronic and certain hospital group purchasing organizations (GPOs) had contracts favoring Medtronic as the 'sole source' for advanced bipolar electrosurgical devices, specifically the LigaSure device [2] - The lawsuit claimed that hospitals faced "financial penalties" and other burdens if they circumvented the GPOs' contracts, which restricted their procurement options [3] Group 2: Court Ruling and Implications - A jury in Los Angeles sided with Applied Medical, confirming that Medtronic used restrictive contracts with healthcare providers [3] - Following the verdict, Applied Medical announced plans to seek injunctive relief to prevent Medtronic from enforcing these restrictions [3] Group 3: Industry Impact - Gary Johnson, a representative for Applied Medical, stated that the ruling validates fair competition and could help hospitals access innovation and value by dismantling complex contractual barriers [4] - Applied Medical emphasized that it was unable to compete effectively with its Voyant device due to Medtronic's restrictive practices and bundling strategies [5] - The company also noted that Medtronic's larger business in other surgical products allegedly conditioned discounts on hospitals purchasing Medtronic's bipolar devices, further stifling competition [6]

These companies pay very healthy dividends.Investors will often debate what makes a good dividend stock. For some, it's all about the dividend yield. Others highlight a company's dividend growth track record. The data suggests the sweet spot is right in the middle. Over the last 50 years, S&P 500 companies that increased their dividends delivered a 10.2% average annual return, while those with no change in their dividend policy (often higher-yielding stocks) returned 6.8% annually, according to data from Ne ...

以下文章来源于AI医疗观察 ，作者关注AI医疗的 AI医疗观察 . 响应《关于深入实施"人工智能+"行动的意见》，推动AI在医疗领域的应用，本账号发布权威资讯 在手术室的角落里，一个 AI引擎正以每秒千次的速度，审阅着全球数万份临床报告，将美敦力一款新心脏起搏器的上市时间悄悄提前了半年；在 GE医疗的全球仓库中，无形的算法网络正实时调度着数万种零部件，悄然锁定了数亿美元本会闲置的现金。 这些没有发布会、不产生炫目 DEMO的"静默革命"，正在成为2026年全球医疗科技领域真正的资本主线。摩根士丹利、贝恩等顶级机构在开年密 集发出报告，核心指向一个颠覆性趋势：聪明的钱，正急速从追逐"AI医疗初创公司"的喧嚣中撤离，转而重仓那些正在用AI系统性改造自己、且 已看到惊人效率提升的传统医疗巨头——美敦力、直觉外科、GE医疗、波士顿科学。 一场由 "效率"定义的静默革命，正在成为2026年全球医疗科技领域真正的资本主线。其核心信号是： 聪明的钱，正急速从追逐 "纯AI工具"的喧 嚣中撤离，转而重仓那些正在用AI系统性改造自己、并能清晰证明效率提升的传统医疗巨头。 行业领袖们并非在产品上简单添加 AI模块，而是正在沿三条 ...

Market Overview - The Surgical Staplers Market was valued at USD 6.41 billion in 2025 and is projected to reach USD 10.87 billion by 2033, growing at a CAGR of 6.87% during the forecast period 2026-2033 [1][20] - The U.S. Surgical Staplers Market is valued at USD 2.03 billion in 2025 and is projected to reach USD 3.19 billion by 2033, growing at a CAGR of 5.82% [4][20] Growth Drivers - The global burden of chronic diseases requiring surgical intervention, rising surgical procedure volumes, and the growing acceptance of minimally invasive surgeries are driving market growth [1] - Over 310 million major surgical procedures are performed globally each year, with a significant portion being minimally invasive, increasing demand for advanced stapling devices [2] - High surgical volumes, rapid adoption of robotic-assisted surgeries, and strong hospital capital expenditure are contributing to growth in the U.S. market [4] Product Segmentation - Manual Surgical Staplers held the largest market share of 58.72% in 2025, while Powered Surgical Staplers are expected to grow at the fastest CAGR of 9.62% during 2026-2033 [9] - Disposable Surgical Staplers dominated with a 63.15% share in 2025, while Reusable Surgical Staplers are projected to expand at a CAGR of 9.47% [10] - Abdominal & Pelvic Surgery accounted for the highest market share of 35.88% in 2025, with Cardiac & Thoracic Surgery anticipated to record the fastest CAGR of 9.84% [11] End-User Insights - Hospitals & Clinics held the largest share of 71.42% in 2025, while Diagnostic Centers are expected to grow at the fastest CAGR of 9.75% during 2026-2033 [12] Regional Insights - North America had the largest market share of 42.58% due to the high number of surgeries and the use of modern stapling technology [15] - The Asia Pacific region is projected to be the fastest-growing, expanding at a CAGR of 8.34% during 2026-2033, driven by rising surgical procedures and healthcare infrastructure [16] Technological Advancements - The use of powered staplers reduces variability of manual force by over 40%, improving surgeon ergonomics and surgical outcomes [5] - Recent product launches include Ethicon's ETHICON4000 Stapler and Medtronic's enhanced Signia™ Stapling System, which feature advanced technologies for improved precision and efficiency [21]

RANCHO SANTA MARGARITA, Calif.--(BUSINESS WIRE)--Applied Medical Prevails in Antitrust Jury Trial Against Medtronic. ...